MS drug Fampyra receives negative opinion from the CHMP

[MSUK]

Biogen Idec announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union.

Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310

[scorpion]

Biogen Idec announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union.

Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310

It just seems that no one can make up their minds about amprya. Usually this means that it is not living up to expectations and will slowly fizzle out!

[RuSmolikova]

Walking speed is not meaningful benefit for european regulator...
<shortened url>